TCF12 and esophageal squamous cell carcinoma: Further mechanistic analysis revealed that Sorafenib treatment enhanced ID1 ubiquitination in ESCC cells (Figure 6Q), disrupting its interaction with TCF12 (Figure 6R) and subsequently promoting the expression of SLC31A1 (Figure 6S‐T).